

# William K Oh

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/54536/william-k-oh-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

353  
papers

13,682  
citations

59  
h-index

107  
g-index

393  
ext. papers

16,313  
ext. citations

6.4  
avg, IF

6.21  
L-index

#	Paper	IF	Citations
353	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5794-9	2.2	1390
352	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3461-7	2.2	839
351	Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 10990-5	11.5	362
350	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2432-8	2.2	349
349	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , <b>2018</b> , 73, 178-211	10.2	313
348	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , <b>2020</b> , 31, 745-759	10.3	303
347	PC3 is a cell line characteristic of prostatic small cell carcinoma. <i>Prostate</i> , <b>2011</b> , 71, 1668-79	4.2	276
346	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1589-604 <sup>10.3</sup>	10.3	220
345	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. <i>Journal of Urology</i> , <b>1998</b> , 160, 1220-1229	2.5	205
344	Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1921-7	2.2	192
343	Functional enhancers at the gene-poor 8q24 cancer-linked locus. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000597	6	189
342	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology</i> , <b>2011</b> , 12, 211-4	21.7	186
341	Castration-resistant prostate cancer: AUA Guideline. <i>Journal of Urology</i> , <b>2013</b> , 190, 429-38	2.5	174
340	Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1439-46	2.2	168
339	Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 44-53	2.2	158
338	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , <b>2020</b> , 77, 508-547	10.2	155
337	Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4416-26	2.2	152

336	Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5233-40	12.9	151
335	The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. <i>Cancer</i> , <b>2017</b> , 123, 3532-3539	6.4	147
334	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2020</b> , 70, 404-423	220.7	147
333	Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. <i>Annals of Oncology</i> , <b>2012</b> , 23, 406-10	10.3	144
332	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2565-73	2.2	134
331	Cabazitaxel. <i>Nature Reviews Drug Discovery</i> , <b>2010</b> , 9, 677-8	64.1	124
330	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 3503	17.4	124
329	Phase II study of sunitinib in men with advanced prostate cancer. <i>Annals of Oncology</i> , <b>2009</b> , 20, 913-20	10.3	122
328	Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 825-32	2.2	116
327	Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. <i>Cancer</i> , <b>2004</b> , 101, 1569-74	6.4	116
326	Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2723-8	2.2	114
325	Evaluation of the 8q24 prostate cancer risk locus and MYC expression. <i>Cancer Research</i> , <b>2009</b> , 69, 5568-74	10.1	102
324	Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 749-61	5	102
323	Adverse event reporting in cancer clinical trial publications. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 83-9	2.2	101
322	Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. <i>Cancers</i> , <b>2014</b> , 6, 1298-327	6.6	99
321	Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3705-12	2.2	99
320	A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. <i>Lancet Oncology</i> , <b>2012</b> , 13, 1105-13	21.7	93
319	Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. <i>Cancer</i> , <b>2008</b> , 112, 1247-53	6.4	91

318	A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. <i>Cancer</i> , <b>2008</b> , 112, 521-6	6.4	89
317	Atypical metastases from prostate cancer: 10-year experience at a single institution. <i>American Journal of Roentgenology</i> , <b>2012</b> , 199, 367-72	5.4	88
316	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. <i>Urology</i> , <b>1999</b> , 54, 1064-7	1.6	88
315	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. <i>Cancer</i> , <b>2009</b> , 115, 981-7	6.4	87
314	Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 842-7	2.2	86
313	Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. <i>Blood</i> , <b>2020</b> , 136, 144-147	2.2	85
312	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. <i>Urology</i> , <b>2003</b> , 62, 324-7	1.6	85
311	A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. <i>Cancer</i> , <b>2003</b> , 98, 2592-8	6.4	81
310	Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5816-24	12.9	80
309	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , <b>2010</b> , 106, 772-8	5.6	73
308	A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal <sup>®</sup> dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). <i>Investigational New Drugs</i> , <b>2011</b> , 29, 1465-74	4.3	71
307	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001204	6	70
306	Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 49-53		69
305	TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. <i>PLoS ONE</i> , <b>2013</b> , 8, e77366	3.7	68
304	Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 727-36	8	68
303	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , <b>2018</b> , 73, 751-759	10.2	67
302	Adult cancer clinical trials that fail to complete: an epidemic?. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	66
301	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. <i>Cancer</i> , <b>2013</b> , 119, 3012-9	6.4	65

300	The evolving role of estrogen therapy in prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2002</b> , 1, 81-9		65
299	Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. <i>BJU International</i> , <b>2012</b> , 110, 1729-35	5.6	64
298	Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. <i>Urology</i> , <b>2011</b> , 78, 626-30	1.6	63
297	Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3577-83	2.2	61
296	CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. <i>Human Pathology</i> , <b>2009</b> , 40, 252-8	3.7	61
295	Sixty years of CA: a cancer journal for clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2010</b> , 60, 345-50	220.7	61
294	Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7099-105	12.9	59
293	A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 924-8	12.9	58
292	Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 40-4	5.5	58
291	Metabolic complications with the use of mTOR inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 190-6	14.4	57
290	Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. <i>BJU International</i> , <b>2010</b> , 105, 1247-54	5.6	56
289	A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. <i>BJU International</i> , <b>2008</b> , 101, 1084-9	5.6	54
288	Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?. <i>Cancer</i> , <b>2007</b> , 109, 477-86	6.4	54
287	A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2004</b> , 22, 393-7	2.8	54
286	Secondary hormonal therapies in the treatment of prostate cancer. <i>Urology</i> , <b>2002</b> , 60, 87-92; discussion 93	1.6	54
285	Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. <i>Urology</i> , <b>2001</b> , 57, 122-6	1.6	54
284	Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. <i>Journal of Urology</i> , <b>2018</b> , 200, 1264-1272	2.5	53
283	Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2627-35	2.2	52

282	Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. <i>Journal of Urology</i> , <b>2015</b> , 194, 91-7	2.5	50
281	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , <b>2019</b> , 76, 599-603	10.2	50
280	Development of an integrated prostate cancer research information system. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 5, 61-6	3.3	50
279	Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. <i>Cancer</i> , <b>2000</b> , 88, 3015-21	6.4	47
278	Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. <i>Urology</i> , <b>2006</b> , 67, 1235-40	1.6	46
277	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. <i>World Journal of Urology</i> , <b>2013</b> , 31, 1535-9	4	45
276	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 919-25	14.4	45
275	Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3223-30	12.9	44
274	Antiandrogens in prostate cancer. <i>Investigational New Drugs</i> , <b>1999</b> , 17, 271-84	4.3	44
273	Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. <i>Cancer</i> , <b>2002</b> , 95, 1864-8	6.4	43
272	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 2202-2211	4.3	42
271	Genome-wide association study of prostate cancer mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 2869-76	4	42
270	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , <b>2016</b> , 70, 771-775	10.2	42
269	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 2065-2080	10.1	41
268	Relationship between serum adiponectin and prostate cancer grade. <i>Prostate</i> , <b>2008</b> , 68, 1592-8	4.2	41
267	Does androgen deprivation therapy protect against severe complications from COVID-19?. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1419-1420	10.3	41
266	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. <i>Cancer</i> , <b>2012</b> , 118, 4777-84	6.4	40
265	Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. <i>Cancer</i> , <b>2006</b> , 107, 530-5	6.4	40

264	Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). <i>BJU International</i> , <b>2012</b> , 110, 1580-8	5.6	39
263	Clinical trial awareness: Changes over time and sociodemographic disparities. <i>Clinical Trials</i> , <b>2015</b> , 12, 215-23	2.2	38
262	Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 719-28	3.2	38
261	Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. <i>Cancer</i> , <b>2006</b> , 107, 975-81	6.4	38
260	The emerging role of circulating tumor cell detection in genitourinary cancer. <i>Journal of Urology</i> , <b>2012</b> , 188, 21-6	2.5	37
259	Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. <i>BJU International</i> , <b>2008</b> , 101, 308-12	5.6	37
258	Photoluminescent polymer nanoparticles for label-free cellular imaging. <i>Chemical Communications</i> , <b>2010</b> , 46, 5229-31	5.8	36
257	Use of crowdsourcing for cancer clinical trial development. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	34
256	The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Urology</i> , <b>2014</b> , 6, 97-104	3.2	34
255	Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. <i>Journal of Visualized Experiments</i> , <b>2015</b> , 53182	1.6	33
254	Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. <i>Journal of Urology</i> , <b>2006</b> , 176, 1927-37	2.5	33
253	Treatment of locally advanced prostate cancer: is chemotherapy the next step?. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3664-75	2.2	33
252	A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 113-23	3.3	32
251	Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. <i>BJU International</i> , <b>2011</b> , 107, 126-34	5.6	32
250	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. <i>Annals of Oncology</i> , <b>2010</b> , 21, 312-318	10.3	32
249	Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5244-51	12.9	32
248	Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2012</b> , 62, 299-308	220.7	31
247	Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. <i>Cancer</i> , <b>2012</b> , 118, 5947-54	6.4	31

246	The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. <i>Cancer</i> , <b>2007</b> , 109, 1090-6	6.4	31
245	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , <b>2014</b> , 44, 5-16	4.4	30
244	Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. <i>Journal of Neurosurgery: Spine</i> , <b>2010</b> , 13, 789-94	2.8	30
243	Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. <i>Cancer</i> , <b>2011</b> , 117, 517-25	6.4	29
242	Multicenter Trial of Single-Dose Modified Bovine Surfactant Extract (Survanta) for Prevention of Respiratory Distress Syndrome. <i>Pediatrics</i> , <b>1990</b> , 85, 1092-1102	7.4	29
241	Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. <i>Clinical Genitourinary Cancer</i> , <b>2012</b> , 10, 15-20	3.3	28
240	Absence of relationship between steroid hormone levels and prostate cancer tumor grade. <i>Urology</i> , <b>2009</b> , 73, 356-61; discussion 361-2	1.6	28
239	A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. <i>Cancer</i> , <b>2006</b> , 106, 58-62	6.4	28
238	Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. <i>Cancer</i> , <b>2000</b> , 89, 1824-8	6.4	28
237	Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1837-40	9.7	27
236	The medical management of prostate cancer: a multidisciplinary team approach. <i>BJU International</i> , <b>2007</b> , 99, 22-7	5.6	26
235	-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 382-392	3.6	26
234	Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e411-e419	3.3	25
233	Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. <i>Annals of Oncology</i> , <b>2004</b> , 15, 974-8	10.3	25
232	Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. <i>Urology</i> , <b>2004</b> , 63, 327-32	1.6	25
231	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma <b>2016</b> , 4, 92		25
230	Recent progress in hormonal therapy for advanced prostate cancer. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 173-8	2.8	24
229	Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. <i>Urology</i> , <b>2002</b> , 60, 1-6	1.6	24



228	The role of ketoconazole in current prostate cancer care. <i>Nature Reviews Urology</i> , <b>2018</b> , 15, 643-651	5.5	23
227	Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?. <i>Urology</i> , <b>2010</b> , 75, 642-7	1.6	23
226	Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 152-8	12.9	23
225	Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. <i>BMJ Open</i> , <b>2020</b> , 10, e040441	3	23
224	Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 500.e1-500.e9	2.8	23
223	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , <b>2019</b> , 76, 782-789	10.2	22
222	The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. <i>Journal of Urology</i> , <b>2015</b> , 194, 36-41	2.5	22
221	Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 2141-2147	4.4	22
220	Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3310-8	12.9	22
219	Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 506-7		22
218	Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. <i>Journal of Urology</i> , <b>2007</b> , 177, 2146-50	2.5	22
217	Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. <i>Urology</i> , <b>2000</b> , 55, 31-5	1.6	22
216	A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 284-9	12.9	22
215	Geographic accessibility to clinical trials for advanced cancer in the United States. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 293-5	11.5	21
214	Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. <i>Cancer</i> , <b>2014</b> , 120, 833-9	6.4	21
213	The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, E71-6	3.3	21
212	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. <i>BJU International</i> , <b>2005</b> , 96, 783-6	5.6	21
211	Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. <i>Cancer</i> , <b>2011</b> , 117, 1172-82	6.4	20

210	Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. <i>BJU International</i> , <b>2010</b> , 105, 1392-6	5.6	20
209	The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 2044-50 <sup>2</sup>	3.2	20
208	Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, 51-7	3.3	20
207	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2021692	10.4	19
206	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab <b>2017</b> , 5, 67		19
205	Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 269-283	19.4	19
204	Trends in the use of cytoreductive nephrectomy in the United States. <i>Clinical Genitourinary Cancer</i> , <b>2012</b> , 10, 159-63	3.3	19
203	Castration-resistant prostate cancer: new science and therapeutic prospects. <i>Therapeutic Advances in Medical Oncology</i> , <b>2010</b> , 2, 189-207	5.4	19
202	Use of androgen deprivation therapy for metastatic prostate cancer in older men. <i>BJU International</i> , <b>2008</b> , 101, 1077-83	5.6	19
201	Correlation of the interpretation of fetal heart rate records with cord plasma erythropoietin levels. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1985</b> , 92, 326-32	3.7	19
200	Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. <i>Cancer</i> , <b>2002</b> , 95, 275-80	6.4	18
199	Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. <i>Urology</i> , <b>2003</b> , 62, 99-104	1.6	18
198	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 1041-1053	15.4	18
197	Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. <i>Urology</i> , <b>2007</b> , 70, 527-31	1.6	17
196	Complementary and alternative therapies in prostate cancer. <i>Seminars in Oncology</i> , <b>2002</b> , 29, 575-84	5.5	17
195	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab <b>2018</b> , 6, 90		17
194	The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. <i>Bladder Cancer</i> , <b>2016</b> , 2, 319-327	1	16
193	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. <i>Targeted Oncology</i> , <b>2014</b> , 9, 195-204	5	16

192	New paradigms in microtubule-mediated endocrine signaling in prostate cancer. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 555-66	6.1	16
191	Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 1871-8	4	16
190	Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 2081-90	3.5	16
189	Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1546-52	12.9	15
188	Male patients with diagnoses of both breast cancer and prostate cancer. <i>Breast Journal</i> , <b>2003</b> , 9, 208-12	1.2	15
187	The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. <i>Journal of Urology</i> , <b>2003</b> , 170, S28-32; discussion S33-4	2.5	15
186	Disease-specific classification using deconvoluted whole blood gene expression. <i>Scientific Reports</i> , <b>2016</b> , 6, 32976	4.9	15
185	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. <i>Oncogene</i> , <b>2018</b> , 37, 5858-5872	9.2	15
184	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	15
183	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). <i>BJU International</i> , <b>2015</b> , 116, 17-29	5.6	14
182	Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	14
181	Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 465-71	3.5	14
180	Bevacizumab treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 1241-9	5.4	14
179	Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, E90-2	3.3	14
178	Renal metabolism in fetal and newborn sheep. <i>Pediatric Research</i> , <b>1985</b> , 19, 641-4	3.2	14
177	Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 397-408	4.3	13
176	The impact of gender on outcomes in patients with metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 346-52	3.3	13
175	Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. <i>Prostate</i> , <b>2015</b> , 75, 616-27	4.2	13

174	Secondary hormonal therapy in men with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2011</b> , 9, 95-103	3.3	13
173	Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?. <i>Urology</i> , <b>2006</b> , 67, 1084.e15-7	1.6	13
172	Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. <i>Journal of Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 2,	0	13
171	A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. <i>BMC Medicine</i> , <b>2015</b> , 13, 201	11.4	12
170	Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 90, 253-61	7	12
169	Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1426-32	8.7	12
168	Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2007</b> , 13, 125-9	2.2	12
167	Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 503-8	2.8	12
166	Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. <i>Cancer</i> , <b>2002</b> , 94, 686-9	6.4	12
165	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. <i>Journal of Urology</i> , <b>1998</b> , 1220-1229	2.5	12
164	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 1605-1612	6.6	11
163	Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. <i>World Journal of Urology</i> , <b>2013</b> , 31, 1211-7	4	11
162	Overcoming castration resistance in prostate cancer. <i>Current Opinion in Urology</i> , <b>2012</b> , 22, 167-74	2.8	11
161	High-risk localized prostate cancer: integrating chemotherapy. <i>Oncologist</i> , <b>2005</b> , 10 Suppl 2, 18-22	5.7	11
160	Prostate cancer characteristics in the World Trade Center cohort, 2002-2013. <i>European Journal of Cancer Prevention</i> , <b>2018</b> , 27, 347-354	2	11
159	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 30.e15-21	2.8	10
158	Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. <i>Clinical Prostate Cancer</i> , <b>2005</b> , 4, 61-4		10
157	The evolving landscape of immunotherapy in advanced prostate cancer. <i>Immunotherapy</i> , <b>2019</b> , 11, 903-918	3.8	9

156	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 48.e1-8	2.8	9
155	Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2012</b> , 30, 848-55	2.8	9
154	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2011</b> , 29, 756-63	2.8	9
153	Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1037-44	10.3	9
152	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4287-4300	12.9	9
151	Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. <i>Medical Oncology</i> , <b>2017</b> , 34, 160	3.7	8
150	Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients. <i>Cancer Investigation</i> , <b>2017</b> , 35, 652-661	2.1	8
149	Neoadjuvant and adjuvant therapies in prostate cancer. <i>Urologic Clinics of North America</i> , <b>2010</b> , 37, 97-104, Table of Contents	2.9	8
148	Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2011</b> , 5, 163-9	1.8	8
147	Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. <i>JCO Clinical Cancer Informatics</i> , <b>2017</b> , 1, 1-10	5.2	7
146	Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. <i>BJU International</i> , <b>2011</b> , 108, 1086-91	5.6	7
145	Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. <i>Cancer</i> , <b>2007</b> , 110, 2709-15	6.4	7
144	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , <b>2021</b> , 64, 2359-2366	10.3	7
143	Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 129	5.3	6
142	Emerging personalized approaches for the management of advanced urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1537-43	3.5	6
141	Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. <i>Cancer</i> , <b>2013</b> , 119, 3020-6	6.4	6
140	Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. <i>Cancer</i> , <b>2003</b> , 97, 2171-9	6.4	6
139	Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2003</b> , 21, 229-34	2.8	6

138	PC-SPEs and prostate cancer. <i>Urologic Clinics of North America</i> , <b>2002</b> , 29, 59-66, viii	2.9	6
137	Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 681-2	21.7	5
136	Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 1259-65	3.5	5
135	An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. <i>Journal of Urology</i> , <b>2004</b> , 172, S34-7; discussion S37	2.5	5
134	PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. <i>Journal of Urology</i> , <b>2002</b> , 167, 1392-1392	2.5	5
133	A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. <i>Cancer</i> , <b>1999</b> , 86, 1329-34	6.4	5
132	Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 256-256	2.2	5
131	A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.. <i>Journal of Clinical Oncology</i>	2.2	5
130	F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. <i>Practical Radiation Oncology</i> , <b>2020</b> , 10, 354-362	2.8	5
129	A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. <i>Prostate</i> , <b>2016</b> , 76, 1160-8	4.2	5
128	Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 1414-e9	5.7	5
127	Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 287-298	5.4	4
126	Metabolic and toxicological considerations of newly approved prostate cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 835-46	5.5	4
125	Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. <i>Clinical Genitourinary Cancer</i> , <b>2011</b> , 9, 27-30	3.3	4
124	Carboplatin for stage I seminoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2971-2; author reply e32-3	2.2	4
123	Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2958-9	2.2	4
122	Chemotherapy for high-risk localized prostate cancer. <i>BJU International</i> , <b>2006</b> , 97, 679-83	5.6	4
121	Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. <i>Journal of Urology</i> , <b>2003</b> , 170, S3-5	2.5	4

120	Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow-up. <i>Prostate Journal</i> , <b>2001</b> , 3, 42-43		4
119	A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. <i>Cancer Investigation</i> , <b>2002</b> , 20, 186-91	2.1	4
118	Nonmalignant diagnoses in patients. Case 3. Right atrial thrombus associated with a central venous catheter in a patient with metastatic adrenocortical carcinoma. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2638-9	2.2	4
117	Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4524-4524	2.2	4
116	Premature termination of genitourinary cancer clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 288-288		4
115	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4586-4586	2.2	4
114	Comparative effectiveness of adjuvant chemotherapy (AC) versus observation in patients with pT3 and/or pN+ bladder cancer (BCa).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 292-292	2.2	4
113	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4538-4538	2.2	4
112	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS3114-TPS3114	2.2	4
111	Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. <i>Oncotarget</i> , <b>2016</b> , 7, 68688-68707	3.3	4
110	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , <b>2016</b> , 2, 341-349		4
109	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 41-41	2.2	4
108	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	4
107	Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHARTED trial. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 638-645	6.2	3
106	Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. <i>Oncologist</i> , <b>2014</b> , 19, 915-6	5.7	3
105	Anemia Related to Hormonal Ablation Therapy for Prostate Cancer. <i>Prostate Journal</i> , <b>2001</b> , 3, 14-17		3
104	PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC). <i>Journal of Urology</i> , <b>1999</b> , 177	2.5	3
103	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , <b>2021</b> , 26, e1226-e1239	5.7	3

102	Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, e23-e33	3.1	3
101	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> ,	6.2	3
100	Progressive sclerosis of isolated foot metastasis of prostate cancer. <i>Journal of Urology</i> , <b>2002</b> , 167, 1392	2.5	3
99	Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy. <i>Current Urology Reports</i> , <b>2015</b> , 16, 13	2.9	2
98	Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. <i>JCO Clinical Cancer Informatics</i> , <b>2017</b> , 1, 1-12	5.2	2
97	CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA). <i>Value in Health</i> , <b>2005</b> , 8, A16-A17	3.3	2
96	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2003</b> , 26, 312-316	2.7	2
95	Neoadjuvant docil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2003</b> , 26, 312-6	2.7	2
94	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.. <i>Oncologist</i> , <b>2022</b> ,	5.7	2
93	Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5015-5015	2.2	2
92	Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10124-10124	2.2	2
91	Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 480-480	2.2	2
90	Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 40-44	5.5	2
89	Prostate Cancer Dormancy and Reactivation in Bone Marrow. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
88	Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. <i>Anti-Cancer Drugs</i> , <b>2016</b> , 27, 235-8	2.4	2
87	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 743-749	6.2	2
86	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , <b>2021</b> , e14669	3.5	2
85	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , <b>2022</b> ,	10.2	2



84	Urological cancer: Is docetaxel the black widow of mCRPC drugs?. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 316-8	19.4	1
83	Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. <i>Brachytherapy</i> , <b>2018</b> , 17, 874-881	2.4	1
82	Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2013</b> , 16, 266-70	6.2	1
81	Renal Cell Carcinoma and Targeted Therapy <b>2015</b> , 287-295		1
80	659 RACIAL AND SOCIOECONOMIC DISPARITIES IN THE UTILIZATION OF NEPHRON-SPARING PROCEDURES FOR STAGE I KIDNEY CANCER IN THE UNITED STATES. <i>Journal of Urology</i> , <b>2012</b> , 187,	2.5	1
79	Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2010</b> , 7, 17-22		1
78	Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. <i>Cases Journal</i> , <b>2009</b> , 2, 7273		1
77	What is the current status of second-line chemotherapy for castration-resistant prostate cancer?. <i>Nature Reviews Urology</i> , <b>2008</b> , 5, 650-1		1
76	Docetaxel in Hormone-Refractory Metastatic Prostate Cancer. <i>Drugs</i> , <b>2005</b> , 65, 2295-2297	12.1	1
75	Neoadjuvant therapy for high-risk localized prostate cancer. <i>Current Oncology Reports</i> , <b>2003</b> , 5, 250-7	6.3	1
74	Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. <i>Journal of Urology</i> , <b>2003</b> , 170, 1305	2.5	1
73	Prostate-specific antigen doubling time predicts disease progression and survival. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 1, 208-11		1
72	Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer. <i>Prostate Journal</i> , <b>1999</b> , 1, 185-189		1
71	Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4623-4623	2.2	1
70	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 398-398	2.2	1
69	Distribution and geographic accessibility of prostate cancer clinical trials in the United States.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 59-59	2.2	1
68	Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 184-184	2.2	1
67	Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15160-e15160	2.2	1

66	Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4656-4656	2.2	1
65	Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9080-9080	2.2	1
64	Lacrimal sac adenocarcinoma managed with androgen deprivation. <i>American Journal of Ophthalmology Case Reports</i> , <b>2020</b> , 19, 100607	1.3	1
63	Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2009</b> , 12, 165-8		1
62	Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 166-166	2.2	0
61	Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 114-120	2.7	0
60	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 734963	5.3	0
59	Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 112-112	2.2	0
58	Renal Cancer <b>2019</b> , 43-55		
57	T2 muscle-invasive bladder cancer. <i>Seminars in Oncology</i> , <b>2014</b> , 41, e11-8	5.5	
56	Endocrine therapy for prostate cancer: review of the latest clinical evidence. <i>Clinical Investigation</i> , <b>2011</b> , 1, 533-541		
55	Cancer therapy from bench to bedside. <i>Mount Sinai Journal of Medicine</i> , <b>2010</b> , 77, 571-2		
54	Docetaxel in Hormone-Refractory Metastatic Prostate Cancer. <i>Drugs</i> , <b>2005</b> , 65, 2295-2297	12.1	
53	Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. <i>Current Treatment Options in Oncology</i> , <b>2004</b> , 5, 349-55	5.4	
52	Metastatic Adenocarcinoma of the Prostate <b>2005</b> , 505-513		
51	Overall Survival after Prostate-Specific-Antigen-Detected Recurrence Following Conformal Radiation Therapy.. <i>Prostate Journal</i> , <b>2001</b> , 3, 43-44		
50	Prospective Trial of the Herbal Supplement PC-SPEC in Patients with Progressive Prostate Cancer.. <i>Prostate Journal</i> , <b>2001</b> , 3, 44-45		
49	Article Reviews. <i>Prostate Journal</i> , <b>2000</b> , 2, 102-105		

48 Article Reviews. *Prostate Journal*, **2000**, 2, 163-167

47 Article Reviews. *Prostate Journal*, **1999**, 1, 103-108

46 Article Reviews. *Prostate Journal*, **1999**, 1, 203-207

45 Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.. *Breast Cancer Research and Treatment*, **2022**, 192, 313 4.4

44 Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?. *Journal of Kidney Cancer and VHL*, **2021**, 8, 13-19 1.4

43 Smoking status and immunotherapy outcomes in smoking-associated cancers.. *Journal of Clinical Oncology*, **2020**, 38, e15097-e15097 2.2

42 What happens at radiographic disease progression in patients with metastatic cancer receiving immune checkpoint inhibitors? A single institution analysis.. *Journal of Clinical Oncology*, **2020**, 38, e15157-e15157 2.2

41 Predictors of successful randomized phase III studies in the treatment metastatic renal cell carcinoma: A meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, e17105-e17105 2.2

40 Does race affect the quality of treatment for intermediate-risk and high-risk prostate cancer?. *Journal of Clinical Oncology*, **2014**, 32, e17678-e17678 2.2

39 Use of crowdsourcing for cancer clinical trial development.. *Journal of Clinical Oncology*, **2014**, 32, e16019-e16019 2.2

38 Impact of obesity in patients with metastatic urothelial carcinoma.. *Journal of Clinical Oncology*, **2015**, 33, 346-346 2.2

37 Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.. *Journal of Clinical Oncology*, **2015**, 33, e16029-e16029 2.2

36 Influence of concurrent diabetes mellitus on clinical progression and response to androgen deprivation therapy in patients with advanced prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, e16036-e16036 2.2

35 Effectiveness of adjuvant chemotherapy (AC) versus observation in patients with T3 and/or pN+ bladder cancer (BCa).. *Journal of Clinical Oncology*, **2015**, 33, 4517-4517 2.2

34 Enzalutamide in Metastatic Castration Resistant Prostate Cancer **2016**, 157-169

33 Frequency and clinical implications of pathologic complete response (pCR) at cystectomy for muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC).. *Journal of Clinical Oncology*, **2016**, 34, 383-383 2.2

32 Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).. *Journal of Clinical Oncology*, **2016**, 34, 5026-5026 2.2

31 Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2016**, 34, e16002-e16002 2.2

- 30 Comparative effectiveness of treatment strategies for urothelial cancer of the bladder (UCB) with clinical lymph node involvement (cN+).. *Journal of Clinical Oncology*, **2016**, 34, 4530-4530 2.2
- 29 Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab.. *Journal of Clinical Oncology*, **2017**, 35, 6-6 2.2
- 28 Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).. *Journal of Clinical Oncology*, **2017**, 35, 36-36 2.2
- 27 Platinum Agents in Prostate Cancer **2010**, 153-161
- 26 Cancer of the Genitourinary Tract **2010**, 233-277
- 25 Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. *Asian Journal of Andrology*, **2011**, 13, 181-2 2.8
- 24 Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Oncotype DX era.. *Journal of Clinical Oncology*, **2012**, 30, e21032-e21032 2.2
- 23 A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 4516-4516 2.2
- 22 Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, e21016-e21016 2.2
- 21 Chemotherapy and Associated Symptoms **2013**, 835-858
- 20 Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2013**, 31, 251-251 2.2
- 19 Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011.. *Journal of Clinical Oncology*, **2013**, 31, 195-195 2.2
- 18 Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2013**, 31, 269-269 2.2
- 17 Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease.. *Journal of Clinical Oncology*, **2013**, 31, e16032-e16032 2.2
- 16 Prevalence and characteristics of prematurely terminated cancer clinical trials.. *Journal of Clinical Oncology*, **2013**, 31, 6613-6613 2.2
- 15 Immune gene expression in primary melanomas to predict lower risk of recurrence and death.. *Journal of Clinical Oncology*, **2013**, 31, 3014-3014 2.2
- 14 Cancer clinical trial accessibility in the United States: An analysis of travel distance.. *Journal of Clinical Oncology*, **2013**, 31, 6540-6540 2.2
- 13 Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development. *Current Clinical Urology*, **2014**, 321-327

12	Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 321-321	2.2
11	Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 28-28	2.2
10	Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 170-170	2.2
9	Geographic and racial disparities in the utilization of low-volume cystectomy hospitals for bladder cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 302-302	2.2
8	Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e17027-e17027	2.2
7	A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 Pandemic. <i>Quality Management in Health Care</i> , <b>2021</b> , 30, 276-279	1
6	Multimodal therapy in the treatment of metastatic prostate cancer: A case report. <i>Urology Case Reports</i> , <b>2018</b> , 21, 92-94	0.5
5	Transitional cell carcinoma of the upper uroepithelial tract. <i>Clinical Advances in Hematology and Oncology</i> , <b>2003</b> , 1, 102-4; discussion 105	0.6
4	Reply to Carlos G. Wambier and Gerard J. Naumik Letter to the Editor re: Karin Welb, Ebba Rosendal, Magnus Gissl, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2021.12.013">https://doi.org/10.1016/j.eururo.2021.12.013</a> Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients	10.2
3	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. <i>Clinical Advances in Hematology and Oncology</i> , <b>2022</b> , 20 Suppl 9, 1-20 <i>European Urology</i> , <b>2022</b> , 81, e143-e143	0.6
2	Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. <i>Clinical Advances in Hematology and Oncology</i> , <b>2022</b> , 20 Suppl 9, 13-16	0.6
1	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.. <i>Clinical Advances in Hematology and Oncology</i> , <b>2022</b> , 20 Suppl 9, 16-17	0.6